Get the Stockscreener App
1.39
0.00%
0.00
After Hours:
1.38
-0.01
-0.72%
Achilles Therapeutics Plc Adr stock is traded at $1.39, with a volume of 2.42M.
It is up +0.00% in the last 24 hours and up +19.83% over the past month.
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
See More
Previous Close:
$1.39
Open:
$1.38
24h Volume:
2.42M
Relative Volume:
5.57
Market Cap:
$57.13M
Revenue:
-
Net Income/Loss:
$-66.88M
P/E Ratio:
-0.8424
EPS:
-1.65
Net Cash Flow:
$-62.91M
1W Performance:
+24.11%
1M Performance:
+19.83%
6M Performance:
+78.37%
1Y Performance:
+51.47%
1-Day Range:
$1.375
$1.39
1-Week Range:
$1.095
$1.41
52-Week Range:
$0.63
$1.76
Achilles Therapeutics Plc Adr Stock (ACHL) Company Profile
Name
Achilles Therapeutics Plc Adr
Sector
Industry
Phone
-
Address
-
Compare ACHL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHL
Achilles Therapeutics Plc Adr
|
1.39 | 57.13M | 0 | -66.88M | -62.91M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Achilles Therapeutics Plc Adr Stock (ACHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | Chardan Capital Markets | Buy |
| Apr-26-21 | Initiated | JP Morgan | Underweight |
| Apr-26-21 | Initiated | Oppenheimer | Outperform |
| Apr-26-21 | Initiated | Piper Sandler | Overweight |
View All
Achilles Therapeutics Plc Adr Stock (ACHL) Latest News
Take off with Fate Therapeutics Inc (FATE): Get ready for trading - SETE News
Top investors say Lam Research Corp (LRCX) ticks everything they need - SETE News
It is Poised to be a Bull Market for Allot Ltd (ALLT) - SETE News
Stocks of Achilles Therapeutics Plc ADR (ACHL) are poised to climb above their peers - SETE News
Piper Sandler gives a Neutral recommendation for Achilles Therapeutics Plc ADR (ACHL) - Knox Daily
Do you want to know where to find good stock? Take a look at Achilles Therapeutics Plc ADR’s (NASDAQ:ACHL) Sentiment Analysis – US Post News - US Post News
JMP Securities downgrades PJT Partners Inc (PJT) rating to a Mkt perform - Knox Daily
Hexcel Corp (HXL) receives an Outperform rating from RBC Capital Mkts - Knox Daily
Lloyds Banking Group plc ADR (LYG) rating downgrades by Morgan Stanley - Knox Daily
Did Caredx Inc (CDNA) perform well in the last session? - US Post News
Examining Immatics N.V (IMTX) more closely is necessary - US Post News
Achilles Therapeutics Plc ADR Inc. (ACHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
TPX’s 2023 Market Dance: Up 18.05% – Time to Invest? - The InvestChronicle
Rezolve AI Ltd: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Head to Head Review: OPHIR ENERGY PL/ADR (OTCMKTS:OPHRY) vs. HOYA (OTCMKTS:HOCPY) - Defense World
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - GlobeNewswire Inc.
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ACHL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Check Out Achilles Therapeutics Plc ADR (ACHL)’s Trade Data Rather Than the Analysts’ Views - SETE News
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
why Achilles Therapeutics Plc ADR [ACHL] is a Good Choice for Investors After New Price Target of $1.25 - The DBT News
What Analysts Were Expecting After PowerFleet Inc (NASDAQ: AIOT) rose 2.40% - Stocks Register
Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter
Achilles Therapeutics ends TIL-based cancer therapy trials - Investing.com
You Should Read This Analysis Before Investing in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) - US Post News
Achilles stock climbs on strategic focus (NASDAQ:ACHL) - Seeking Alpha
Achilles Therapeutics Announces Strategic Update - Yahoo Finance
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire
Achilles Therapeutics Announces Research Collaboration with - GlobeNewswire
Achilles Therapeutics faces Nasdaq delisting over share price - Investing.com
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights - GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis - Yahoo Finance
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock - Yahoo Finance
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study - Yahoo Finance
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 - Yahoo Finance
Novo (NVO) Posts Positive Data From Diabetes Study on CagriSema - Nasdaq
Achilles Therapeutics PlcADR Shares Close the Day 10.1% HigherDaily Wrap - Nasdaq
Achilles Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Achilles Therapeutics Plc Adr Stock (ACHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):